There’s one end­point that the boom­ing bio­phar­ma in­dus­try has failed at mis­er­ably: fi­nan­cial tox­i­c­i­ty

6 years ago
Bioregnum
R&D

Aca­di­a's sweep­ing hunt for bet­ter Nu­plazid da­ta bags mixed re­sults for schiz­o­phre­nia

6 years ago
R&D

OPDP let­ter crit­i­cizes drug com­pa­ny for fail­ing to dis­close risk in­fo on­line

6 years ago
R&D

Velox­is wins $1.3B buy­out, and the new own­er plans to fol­low up with new deals

6 years ago
Deals

La Jol­la CEO de­camps just as biotech faces a reck­on­ing for iron over­load drug

6 years ago
R&D

Make that 2 new sick­le cell dis­ease block­buster hope­fuls OK’d by the FDA in just a few days

6 years ago
R&D
FDA+

Shares of Adamis crater on CRL; Boris John­son promis­es to dou­ble de­men­tia re­search fund­ing

6 years ago
News Briefing

CymaBay scraps key NASH, PSC pro­grams af­ter lead drug trig­gers safe­ty alarms — share price im­plodes

6 years ago
R&D

Ex-Pur­due CEO stands to earn a huge wind­fall in No­var­tis' buy­out of the Med­i­cines Co

6 years ago
People
Deals

‘Break­through’ blad­der can­cer drug spin­out gets $570M to back launch of a new gene ther­a­py in the US

6 years ago
Startups
Deals

The big drug hunters: No­var­tis’ $28B-plus deal spree makes Vas Narasimhan one of the top deal­mak­ers of our time

6 years ago

Roche, PTC will now get an FDA de­ci­sion on their SMA drug in 6 months — fac­ing off with Bio­gen, No­var­tis

6 years ago
R&D
FDA+

Aque­s­tive nabs FDA OK for oral film ver­sion of gener­ic ALS drug

6 years ago
Pharma
FDA+

Roche shows Tecen­triq/Avastin com­bo helps liv­er can­cer pa­tients live longer

6 years ago
R&D
China

Har­vard con­sor­tium blue­prints $50M cell and gene ther­a­py cen­ter — but can they ac­tu­al­ly fos­ter low­er drug prices?

6 years ago
R&D

Ac­quis­i­tive No­var­tis bags PC­SK9 play­er Med­Co for $9.7B, set­ting up a flank at­tack on Sanofi, Re­gen­eron and Am­gen

6 years ago
Deals
R&D

With lat­est 18-month da­ta cut, Take­da push­es to­ward 2021 launch of dengue vac­cine — can they side­step Sanofi's ...

6 years ago
R&D

Take­da an­nounces pos­i­tive new ALK+ lung can­cer da­ta as list of crizo­tinib suc­ces­sors widens

6 years ago
R&D

Cel­gene R&D vet jumps to biotech: 'It’s about short­en­ing the cy­cle'; No­var­tis ex­o­dus con­tin­ues as William Chou ...

6 years ago
Peer Review

Japan­ese biotech pitch­ing iP­SC-de­rived med for the heart gains $26M; An­dreessen Horowitz leads $4.1M seed fund­ing for ...

6 years ago
News Briefing

Team­ing up with NIH, Vi­iV buys in­to the next big thing in HIV: an­ti­bod­ies

6 years ago
Deals

FDA re­leas­es 81 prod­uct-spe­cif­ic guid­ances

6 years ago
Pharma
FDA+

Alexan­dria is think­ing big as it lays out plans for 1.6M square foot Bay Area biotech cam­pus

6 years ago
R&D

Put on hold mu­sic: Roche de­lays Spark buy­out for the 9th — and quite pos­si­bly not the last — time

6 years ago
R&D
First page Previous page 877878879880881882883 Next page Last page
A service from the Financial Times